Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 3/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.49 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 3/20 | 0.48 |
| ▸ | YARS1 | P54577 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7709347 | 1.00 | NAALAD2 (0.54) | NAALAD2ACEFOLH1CA1CA2 | |
| SCHEMBL7703636 | 0.95 | MME (0.50) | NAALAD2ACEFOLH1CA1CA2 | |
| SCHEMBL28794655 | 0.95 | CA1 (0.53) | NAALAD2ACEFOLH1CA1CA2 | |
| SCHEMBL4147882 | 0.90 | NAALAD2 (0.61) | NAALAD2ACEFOLH1CA1CA2 | |
| SCHEMBL4147877 | 0.90 | NAALAD2 (0.61) | NAALAD2ACEFOLH1CA1CA2 | |
| SCHEMBL4147927 | 0.86 | ITGB3 (0.62) | NAALAD2ACEFOLH1ITGB3ITGA2B | |
| SCHEMBL4147924 | 0.86 | ITGB3 (0.62) | NAALAD2ACEFOLH1ITGB3ITGA2B | |
| SCHEMBL4147417 | 0.86 | ITGB3 (0.62) | NAALAD2ACEFOLH1ITGB3ITGA2B | |
| SCHEMBL4147413 | 0.86 | ITGB3 (0.62) | NAALAD2ACEFOLH1ITGB3ITGA2B | |
| SCHEMBL5370755 | 0.85 | ERCC1 (0.52) | CA1CA2ERCC1ERCC4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223793-B2 | Phenolic acid derivatives and composition for preventing or treating blood lipid level-related diseases comprising the same | BIONUTRIGEN CO., LTD. (KR) | 2007-05-29 | — | — | US | disclosed |
| US-20030199566-A1 | Phenolic acid derivatives and composition for preventing or treating blood lipid level-related diseases comprising the same | BIONUTRIGEN CO., LTD. (KR) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199566-A1 | Phenolic acid derivatives and composition for preventing or treating blood lipid level-related diseases comprising the same | NCEH1, HMGCR, DBH | NAALAD2 914/4885ACE 1230/4885FOLH1 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.